Christin Helmschrodt, Sabrina Höbel, Sandra Schöniger, Anne Bauer, Jana Bonicelli, Marieke Gringmuth, Simone A Fietz, Achim Aigner, Angelika Richter, Franziska Richter
RNA interference (RNAi)-based strategies that mediate the specific knockdown of target genes by administration of small interfering RNAs (siRNAs) could be applied for treatment of presently incurable neurodegenerative diseases such as Parkinson's disease. However, inefficient delivery of siRNA into neurons hampers in vivo application of RNAi. We have previously established the 4-12 kDa branched polyethylenimine (PEI) F25-LMW with superior transfection efficacy for delivery of siRNA in vivo. Here, we present that siRNA complexed with this PEI extensively distributes across the CNS down to the lumbar spinal cord after a single intracerebroventricular infusion...
December 15, 2017: Molecular Therapy. Nucleic Acids